Developer docs
API playgroundTry for free, no card

Search company profiles

LifeSci Venture Partners

Full company profile

uuid0002huh

Namestring
LifeSci Venture Partners
Legal namestring
LifeSci Venture Partners
Websiteurl
lifesciventure.com
Company typeenum
Private
Founded yearint
2020
Short descriptiontext

LifeSci Venture Partners is a privately-held, New York-based healthcare venture capital firm investing in clinical-stage biotech and healthtech companies targeting public-market transitions within 12-18 months, supported by an affiliated consultancy platform of over 200 professionals.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
healthcare venture capital, clinical-stage biotech investing, life sciences investment, biotech growth capital, healthcare innovation funding
Industry3 codes
1Sector-Focused Venture Capital (Vertical Specialists)
CodeFSANAAADPrimaryYes
2Healthcare & Life Sciences Growth Equity
CodeFSANACABPrimaryNo
3Late-Stage Venture Capital (Series C+)
CodeFSANAAACPrimaryNo
NAICS code2 codes
  • Other Financial Investment Activities5239
  • Securities, Commodity Contracts, and Other Financial Investments and Related Activities523
SIC code2 codes
  • Investment Advice6282
  • Services-Management Consulting Services8742
Product category
Venture Capital
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Investment Returns
TypeProfessional Services
Description

LifeSci Venture Partners generates returns through equity investments in portfolio companies, including through fund management fees and carried interest from successful exits.

lifesciventure.com
2LifeSci Partners Services
TypeProfessional Services
Description

Revenue generated through affiliated LifeSci Partners platform offering consulting, investment banking, executive recruiting, communications, and event planning services to portfolio companies and external clients.

lifesciventure.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1LifeSci Partners Platform
Description

A global healthcare consultancy platform with over 200 experienced professionals offering LifeSci Events, LifeSci Advisors, LifeSci Communications, LifeSci Search, LifeSci Capital, and LifeSci Consulting services

lifesciventure.com
Core offering1 text field

LifeSci Venture Partners is a New York-based venture capital firm that invests in clinical-stage healthcare and biotech companies aiming to transition to public markets within 12-18 months. The firm provides founder-aligned, patient capital alongside operational support through its affiliated LifeSci Partners platform, which delivers consulting, investor relations, communications, executive recruiting, investment banking, and event planning services to portfolio companies.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

LifeSci Venture Partners operates as a venture capital firm offering a unified investment platform focused on healthcare innovation. The core offering is their investment services targeting clinical-stage opportunities in biotech and healthcare technology, supplemented by the LifeSci Partners Platform—a comprehensive consultancy ecosystem encompassing LifeSci Events, LifeSci Advisors, LifeSci Communications, LifeSci Search, LifeSci Capital, and LifeSci Consulting. Together, these services provide capital deployment, strategic advisory, and operational support to portfolio companies.

Product and service1 record
1Healthcare Investment Services
Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
1SK Biopharmaceuticals
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-11-02
Description

SK Biopharmaceuticals and LifeSci Venture Partners forged ties for open innovation. This partnership represents a strategic collaboration in the healthcare/biotech innovation space, combining SK Biopharmaceuticals' pharmaceutical capabilities with LifeSci's venture capital expertise and network.

2LifeSci Partners Platform
Strategic tierCoreTypeOthers
Description

LifeSci Partners is an affiliated global healthcare consultancy with over 200 experienced professionals across multiple business verticals including LifeSci Events, LifeSci Advisors, LifeSci Communications, LifeSci Search, LifeSci Capital, and LifeSci Consulting. This platform provides comprehensive support services to LifeSci Venture Partners portfolio companies.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
1Foresite Capital
TypeDirect peer
Description

Healthcare and life sciences-focused investment firm investing across public and private stages, with biotech specialization. Direct comparable—co-invested alongside LifeSci in the Quince/Orphai private placement.

2Atlas Venture
TypeDirect peer
Description

Early-stage life sciences venture firm that builds and invests in biotech startups, particularly in genomics, cell therapy, and rare diseases. Comparable as a clinical-stage-focused, science-driven healthcare VC operating with a small, expert team.

3OrbiMed
TypeDirect peer
Description

One of the largest dedicated healthcare investment firms globally, investing across stages in biotech, medical devices, and diagnostics. Direct comparable as a sector-specialized healthcare VC with deep scientific underwriting and a broad portfolio in clinical-stage opportunities.

4RA Capital Management
TypeDirect peer
Description

Healthcare-focused investment manager with both public and private strategies, leading clinical-stage financings across biotech. Direct peer that frequently leads and co-invests in the same clinical-stage rounds LifeSci targets (e.g., Veradermics, Quince ecosystem).

55AM Ventures
TypeDirect peer
Description

Early-stage venture capital firm focused on building next-generation life science companies, with concentration in biotech and platform technologies. Highly comparable as a clinical-stage-biotech-focused VC with a hands-on operating model.

6Medicxi
TypeDirect peer
Description

Asset management firm focused on life sciences, investing across the full company lifecycle in pharma and biotech. Comparable as a clinical-stage-focused healthcare VC operating with a relatively small, expert team.

7ARCH Venture Partners
TypeDirect peer
Description

Large early-stage healthcare and technology venture firm with deep involvement in biotech formation and clinical development. Comparable as a long-tenured, science-led VC investing heavily in transformative clinical-stage companies.

8venBio Partners
TypeDirect peer
Description

Life sciences-focused venture firm partnering with entrepreneurs to develop novel therapeutic products, with portfolio overlap in clinical-stage biotech. Comparable as a healthcare-specialized VC with strong scientific and clinical orientation.

9Perceptive Advisors
TypeDirect peer
Description

Healthcare-focused investment firm with public and private strategies, frequently leading and co-investing in clinical-stage biotech rounds. Direct peer that participated in the same Quince/Orphai financing as LifeSci and operates across the same clinical-stage deal universe.

10Sofinnova Investments
TypeDirect peer
Description

One of the oldest healthcare-dedicated VC firms in Europe, with a portfolio of clinical and commercial-stage life sciences companies. Comparable as a long-tenured, sector-specialized life sciences VC with global deal flow.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles5 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment58 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

LifeSci Venture Partners

Venture Capitallifesciventure.com

LifeSci Venture Partners is a privately-held, New York-based healthcare venture capital firm investing in clinical-stage biotech and healthtech companies targeting public-market transitions within 12-18 months, supported by an affiliated consultancy platform of over 200 professionals.

LifeSci Venture Partners firmographics

Firmographics
Name
LifeSci Venture Partners
Legal name
LifeSci Venture Partners
Website
https://lifesciventure.com
Company type
Private
Founded year
2020
Operating status
Operating
Headcount range
1–10 employees
Short description
LifeSci Venture Partners is a privately-held, New York-based healthcare venture capital firm investing in clinical-stage biotech and healthtech companies targeting public-market transitions within 12-18 months, supported by an affiliated consultancy platform of over 200 professionals.
Ownership category
akta.pro rank

LifeSci Venture Partners industry classification

Industry
Product category
Venture Capital
NAICS
Other Financial Investment Activities (5239), Securities, Commodity Contracts, and Other Financial Investments and Related Activities (523)
SIC
Investment Advice (6282), Services-Management Consulting Services (8742)
akta.pro primary industry
Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
akta.pro secondary industries
Healthcare & Life Sciences Growth Equity (FSANACAB), Late-Stage Venture Capital (Series C+) (FSANAAAC)

Keywords

  • Healthcare venture capital
  • Clinical-stage biotech investing
  • Life sciences investment
  • Biotech growth capital
  • Healthcare innovation funding

Where LifeSci Venture Partners is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

LifeSci Venture Partners business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

  1. Investment Returns: LifeSci Venture Partners generates returns through equity investments in portfolio companies, including through fund management fees and carried interest from successful exits.
  2. LifeSci Partners Services: Revenue generated through affiliated LifeSci Partners platform offering consulting, investment banking, executive recruiting, communications, and event planning services to portfolio companies and external clients.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

LifeSci Venture Partners product offering

Product offering

Core offering

LifeSci Venture Partners is a New York-based venture capital firm that invests in clinical-stage healthcare and biotech companies aiming to transition to public markets within 12-18 months. The firm provides founder-aligned, patient capital alongside operational support through its affiliated LifeSci Partners platform, which delivers consulting, investor relations, communications, executive recruiting, investment banking, and event planning services to portfolio companies.

Product overview

LifeSci Venture Partners operates as a venture capital firm offering a unified investment platform focused on healthcare innovation. The core offering is their investment services targeting clinical-stage opportunities in biotech and healthcare technology, supplemented by the LifeSci Partners Platform—a comprehensive consultancy ecosystem encompassing LifeSci Events, LifeSci Advisors, LifeSci Communications, LifeSci Search, LifeSci Capital, and LifeSci Consulting. Together, these services provide capital deployment, strategic advisory, and operational support to portfolio companies.

Differentiator

Problem solved

Functional benefit

Brands

  • LifeSci Partners Platform: A global healthcare consultancy platform with over 200 experienced professionals offering LifeSci Events, LifeSci Advisors, LifeSci Communications, LifeSci Search, LifeSci Capital, and LifeSci Consulting services

Products and services

  • Healthcare Investment Services

Companies that use LifeSci Venture Partners

Customer profile

Named customers3 records

Segments3 records

Ideal customer profiles1 record

LifeSci Venture Partners technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

LifeSci Venture Partners partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • SK BiopharmaceuticalscoreStrategic or Co-development Partner · 2 November 2020SK Biopharmaceuticals and LifeSci Venture Partners forged ties for open innovation. This partnership represents a strategic collaboration in the healthcare/biotech innovation space, combining SK Biopharmaceuticals' pharmaceutical capabilities with LifeSci's venture capital expertise and network.
  • LifeSci Partners PlatformcoreOthersLifeSci Partners is an affiliated global healthcare consultancy with over 200 experienced professionals across multiple business verticals including LifeSci Events, LifeSci Advisors, LifeSci Communications, LifeSci Search, LifeSci Capital, and LifeSci Consulting. This platform provides comprehensive support services to LifeSci Venture Partners portfolio companies.

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

LifeSci Venture Partners competitors and assessment

Company assessment

Direct peers

  • Foresite Capital: Healthcare and life sciences-focused investment firm investing across public and private stages, with biotech specialization. Direct comparable—co-invested alongside LifeSci in the Quince/Orphai private placement.
  • Atlas Venture: Early-stage life sciences venture firm that builds and invests in biotech startups, particularly in genomics, cell therapy, and rare diseases. Comparable as a clinical-stage-focused, science-driven healthcare VC operating with a small, expert team.
  • OrbiMed: One of the largest dedicated healthcare investment firms globally, investing across stages in biotech, medical devices, and diagnostics. Direct comparable as a sector-specialized healthcare VC with deep scientific underwriting and a broad portfolio in clinical-stage opportunities.
  • RA Capital Management: Healthcare-focused investment manager with both public and private strategies, leading clinical-stage financings across biotech. Direct peer that frequently leads and co-invests in the same clinical-stage rounds LifeSci targets (e.g., Veradermics, Quince ecosystem).
  • 5AM Ventures: Early-stage venture capital firm focused on building next-generation life science companies, with concentration in biotech and platform technologies. Highly comparable as a clinical-stage-biotech-focused VC with a hands-on operating model.
  • Medicxi: Asset management firm focused on life sciences, investing across the full company lifecycle in pharma and biotech. Comparable as a clinical-stage-focused healthcare VC operating with a relatively small, expert team.
  • ARCH Venture Partners: Large early-stage healthcare and technology venture firm with deep involvement in biotech formation and clinical development. Comparable as a long-tenured, science-led VC investing heavily in transformative clinical-stage companies.
  • venBio Partners: Life sciences-focused venture firm partnering with entrepreneurs to develop novel therapeutic products, with portfolio overlap in clinical-stage biotech. Comparable as a healthcare-specialized VC with strong scientific and clinical orientation.
  • Perceptive Advisors: Healthcare-focused investment firm with public and private strategies, frequently leading and co-investing in clinical-stage biotech rounds. Direct peer that participated in the same Quince/Orphai financing as LifeSci and operates across the same clinical-stage deal universe.
  • Sofinnova Investments: One of the oldest healthcare-dedicated VC firms in Europe, with a portfolio of clinical and commercial-stage life sciences companies. Comparable as a long-tenured, sector-specialized life sciences VC with global deal flow.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

LifeSci Venture Partners social profiles

Digital presence

LifeSci Venture Partners financial estimates

Financial estimate

Revenue estimate

Valuation estimate

LifeSci Venture Partners leadership team

Management profile

Number of profiles

Profiles5 records

LifeSci Venture Partners funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

LifeSci Venture Partners M&A and investment

M&A and investment

M&A

Investments58 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LifeSci Venture Partners

What does LifeSci Venture Partners do?

LifeSci Venture Partners is a New York-based venture capital firm that invests in clinical-stage healthcare and biotech companies aiming to transition to public markets within 12-18 months. The firm provides founder-aligned, patient capital alongside operational support through its affiliated LifeSci Partners platform, which delivers consulting, investor relations, communications, executive recruiting, investment banking, and event planning services to portfolio companies.

Is LifeSci Venture Partners a public or private company?

LifeSci Venture Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was LifeSci Venture Partners founded?

LifeSci Venture Partners was founded in 2020. It employs 1 to 10 people.

Where is LifeSci Venture Partners based?

LifeSci Venture Partners is headquartered in New York, United States, in the North America region.

How does LifeSci Venture Partners make money?

Two revenue lines are on record. Investment Returns are the primary driver. The others are lifeSci Partners Services.

Who are LifeSci Venture Partners's main competitors?

Direct peers on record are Foresite Capital, Atlas Venture, OrbiMed, RA Capital Management, 5AM Ventures, Medicxi, ARCH Venture Partners, venBio Partners, Perceptive Advisors and Sofinnova Investments.

Does LifeSci Venture Partners have an API?

No public API is recorded for LifeSci Venture Partners.

What industry is LifeSci Venture Partners in?

LifeSci Venture Partners's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANACAB, Healthcare & Life Sciences Growth Equity. Its NAICS code is 5239 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpaceYarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business UpdateYarrow Bioscience reported Q2 2026 results with a $6.5M net loss and $18.7M cash, and initiated its Phase 2a/2b trial of YB-101 for Graves' disease. The company expects Phase 2a topline data in the second half of 2027 and plans to fund operations into 2028.GlobeNewswireBoundless Bio and Serapha Bio Announce Merger Agreement and $230 Million Concurrent Private PlacementBoundless Bio and Serapha Bio announced an all-stock merger, with Serapha to operate as the combined company. Serapha secured $230 million in pre-closing private investments, and the deal is expected to close in Q4 2026. The combined company will focus on SERP-01, a base editing therapy for Alpha-1 Antitrypsin Deficiency.BioSpaceQuince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary PipelineQuince Therapeutics acquired Orphai Therapeutics, adding LAM-001, an inhaled rapamycin for pulmonary diseases, to its pipeline. The deal includes a private placement raising up to $187 million, with $115 million upfront and up to $72 million more from warrants. Proceeds are expected to fund operations through 2028 and support Phase 2b trial initiation in PH-ILD.ThedermdigestOne to Watch: Veradermics Raises $150M in Series C Financing; Shares Positive Preliminary Phase 2 Data for Oral Minoxidil in Pattern Hair LossVeradermics has completed an oversubscribed $150 million Series C financing round led by SR One, with participation from Viking Global Investors, Marshall Wace, Invus, abrdn Inc., Columbia Threadneedle Investments, Infinitium, LifeSci Venture Partners, Longitude Capital, Suvretta Capital Management, Surveyor Capital (a Citadel company), and other investors, to fund the registrational development and planned NDA submission for VDPHL01, its lead extended-release oral minoxidil product for pattern hair loss. Preliminary Phase 2 data from the male cohort showed participants achieved an average increase of 37.5 hairs/cm² at two months and 47.3 hairs/cm² at four months, with 95% expressing increased satisfaction by month four, and no serious adverse events including cardiac events were observed. The company has initiated three Phase 3 clinical trials in men and women, with plans to submit an NDA to the FDA pending supportive data.RevbiosciencesNews-22 — Revelation BioSciencesPetra Acquisition, Inc. announced the entry into backstop and forward purchase agreements totaling up to $12 million with institutional investors to support its proposed business combination with Revelation Biosciences, Inc. These agreements are designed to ensure minimum cash conditions are met for the merger and provide working capital for Revelation to continue developing its respiratory viral infection therapy, REVTx-99. The deal involves key financial commitments from AXA Prime Impact Master Fund, Meteora Capital Partners, and LifeSci Venture Partners.GlobeNewswireIridia Raises $24 Million in Series B FundingIridia closed a $24 million Series B financing led by LifeSci Venture Partners, with participation from Western Digital Capital and others. The company's DNA-based memory chips aim to increase data density and reduce carbon footprints. The round will accelerate development of the first DNA-based memory chips.PR NewswireSK Biopharmaceuticals and LifeSci Venture Partners Forge Ties for Open InnovationSK Biopharmaceuticals and LifeSci Venture Partners signed an agreement to collaborate on open innovation through a fund that will invest in private healthcare companies developing novel therapies. The fund, LifeSci Venture Partners II, was launched in 2020 and has made private investments in companies with oncology and CNS expertise.FinSMEsAttune Pharmaceuticals Closed $23M Series B FinancingAttune Pharmaceuticals closed a $23M Series B financing led by Venrock Healthcare Partners with new investor LifeSci Venture Partners. The funds will advance its pipeline, including ATN-249, an oral kallikrein inhibitor for Hereditary Angioedema, which has completed phase 1 studies.GlobeNewswireAttune Pharmaceuticals Announces $23M Series B Financing to Advance ATN-249 for the Treatment of HAEAttune Pharmaceuticals completed a $23 million Series B financing led by Venrock Healthcare Partners, with new investor LifeSci Venture Partners. Proceeds will advance ATN-249, an oral kallikrein inhibitor for Hereditary Angioedema, which showed safety and tolerability in Phase 1. The company plans to move the program into Phase 2.GlobeNewswireLifeSci Venture Partners’ Paul Yook to Moderate Panel at MedCity INVEST ConferencePaul Yook, General Partner at LifeSci Venture Partners, will moderate the opening panel at MedCity INVEST in Chicago on May 17-18, 2017. The panel, titled 'What's Hot in Biopharma Investing? ', features Jack Gilbert, Ed Mathers, and Ilan Zipkin discussing biopharma trends and the future of the field.